Quinacrine Inhibits Icam-1 Transcription By Blocking Dna Binding Of The Nf-Kappa B Subunit P65 And Sensitizes Human Lung Adenocarcinoma A549 Cells To Tnf-Alpha And The Fas Ligand

Quinacrine has been used for therapeutic drugs in some clinical settings. In the present study, we demonstrated that quinacrine decreased the expression of intercellular adhesion molecule-1 (ICAM-1) induced by tumor necrosis factor (TNF)-alpha and interleukin-1 (IL-1) alpha in human lung adenocarcinoma A549 cells. Quinacrine inhibited ICAM-1 mRNA expression and nuclear factor kappa B (NF-kappa B)-responsive luciferase reporter activity following a treatment with TNF-alpha and IL-1 alpha. In the NF-kappa B signaling pathway, quinacrine did not markedly affect the TNF-alpha-induced degradation of the inhibitor of NF-kappa B or the TNF-alpha-induced phosphorylation of the NF-kappa B subunit, p65, at Ser-536 and its subsequent translocation to the nucleus. In contrast, a chromatin immunoprecipitation assay showed that quinacrine prevented the binding of p65 to the ICAM-1 promoter following TNF-alpha stimulation. Moreover, TNF-alpha and the Fas ligand effectively reduced the viability of A549 cells in the presence of quinacrine only. Quinacrine down-regulated the constitutive and TNF-alpha-induced expression of c-FLIP and Mcl-1 in A549 cells. These results revealed that quinacrine inhibits ICAM-1 transcription by blocking the DNA binding of p65 and sensitizes A549 cells to TNF-alpha and the Fas ligand.